.
DNLI financial statements
* Numbers in millions
Year |
2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|
Capitalization * |
354 | 1 751 | 2 226 | 8 281 | 3 674 |
EV * |
136 | 1 673 | 2 150 | 7 778 | 7 778 |
Stock price $ |
23.67 | 18.9 | 23.28 | 68.5 | 30.39 |
Number of shares * |
15 | 93 | 96 | 121 | 121 |
EPS |
-5,89 | -0,39 | -2,07 | 0,59 | 0,59 |
Revenue * |
0 | 129 | 27 | 336 | 336 |
Net income * |
-88 | -36 | -198 | 71 | 71 |
Operating profit * |
-90 | -46 | -213 | 63 | 63 |
Total liabilities * |
21 | 115 | 158 | 454 | 454 |
Net debt * |
-218 | -77 | -7 | -438 | -438 |
Total assets * |
487 | 662 | 553 | 1 604 | 1 604 |
Equity * |
466 | 547 | 395 | 1 151 | 1 151 |
Cash and investments * |
406 | 464 | 415 | 1 470 | 1 470 |
Over the past 10 years, the maximum capitalization of Denali Therapeutics Inc. is 8 281, the minimum is 354. Maximum net income 71, Minimum net income -198. The maximum price of DNLI shares is 68.5, the minimum price is 18.9.
.
DNLI valuation
Year |
2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|
P/E |
-4,02 | -48,30 | -11,26 | 116,41 | 51,64 |
P/B |
0,76 | 3,20 | 5,64 | 7,20 | 3,19 |
P/S |
0,00 | 13,55 | 83,43 | 24,67 | 10,94 |
E/P |
-25% | -2% | -9% | 1% | 2% |
P/FCF |
-4,45 | 37,47 | -13,13 | 20,05 | 8,89 |
.
DNLI profitability
Year |
2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|
ROE |
-19% | -7% | -50% | 6% | |
ROA |
-18% | -5% | -36% | 4% | |
ROIC |
-19% | -7% | -42% | 4% |